Based on the presented data, we concluded that ɑCD4 synergizes with Tx by initiating a wave of de novo priming, that these new tumor-infiltrating T cells are supported by the local ɑ4-1BB-LAIR agonist and TA99, and that this two-step process ultimately drives therapeutic efficacy. The gene discussed is TNFRSF9; the disease is neoplasm.